What compounds target BRAF?

BiohacksAI has identified 45 compounds that interact with BRAF (B-Raf proto-oncogene, serine/threonine kinase). Top compounds include: gefitinib, erlotinib, imatinib, sb 203580, Sorafenib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is BRAF (B-Raf proto-oncogene, serine/threonine)?

BRAF is B-Raf proto-oncogene, serine/threonine kinase. It is a molecular target for 45 compounds documented in PubMed bioassay data. UniProt ID: P15056. NCBI Gene ID: 673.

BRAF

MOLECULAR TARGET

B-Raf proto-oncogene, serine/threonine kinase

UniProt: P15056 NCBI Gene: 67345 compounds

BRAF (B-Raf proto-oncogene, serine/threonine kinase) is targeted by 45 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting BRAF

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	gefitinib	5.67	290
2	erlotinib	5.55	256
3	imatinib	5.47	236
4	sb 203580	4.92	136
5	Sorafenib	4.48	87
6	foretinib	4.34	76
7	Vemurafenib	4.33	75
8	ponatinib	4.26	70
9	ruxolitinib	4.23	68
10	nilotinib	4.17	64
11	pi 103	4.17	64
12	doramapimod	4.06	57
13	pazopanib	3.69	39
14	abemaciclib	3.66	38
15	sb 202190	3.64	37
16	regorafenib	3.56	34
17	bms 387032	3.47	31
18	fedratinib	3.40	29
19	dabrafenib	3.30	26
20	mirdametinib	3.18	23
21	gw305074x	3.14	22
22	dasatinib anhydrous	3.09	21
23	r 406	2.83	16
24	infigratinib	2.77	15
25	masitinib	2.77	15
26	plx 4720	2.71	14
27	cobimetinib	2.64	13
28	ast 487	2.56	12
29	raf 265	2.48	11
30	motesanib	2.48	11
31	sb590885	2.40	10
32	avutometinib	2.30	9
33	rebastinib	2.20	8
34	encorafenib	2.20	8
35	tg100 115	2.08	7
36	amg 900	2.08	7
37	ly 3009120	2.08	7
38	cep 32496	1.95	6
39	bafetinib	1.95	6
40	maleimide	1.95	6
41	bastadin 7	1.95	6
42	naporafenib	1.95	6
43	Dasatinib	1.10	2
44	myricetin-3-O-galactopyranoside [Supplementary Concept]	0.69	1
45	Quercetin	0.69	1

About BRAF as a Drug Target

BRAF (B-Raf proto-oncogene, serine/threonine kinase) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 45 compounds with documented BRAF interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

BRAF inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.